Key facts
- It has raised $100.0M; the latest was Early Stage VC in Jun 2024.
- Notable investors include Legend Capital, Baidu Ventures, Lanchi Ventures, Xiang He Capital, Hong Kong investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BioMap
- ·The full record, as it builds
Funding rounds
No funding rounds for BioMap are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioMap
Developer of foundation models designed to drive new drug research and development. The company utilizes artificial intelligence to allow scientists to model life more accurately from proteins to a system level and extract novel insights and predictions from limited data, supported by an international, cross-functional team, enabling physicians to enhance the effectiveness rate of new drugs.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2020
- Employees
- 200
- Website
- biomap.com/
- Ownership
- Privately Held (backing)
BioMap doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioMap shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioMap in its N-PORT filings yet. We sweep new filings monthly.